Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
There’s no direct link between vision loss and taking the weight loss and diabetes drugs such as Ozempic, Wegovy, Mounjaro, ...
Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...
Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. Here are ...
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...
Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
Several patients using brand-name drugs like Ozempic, Wegovy, Mounjaro, and Zepbound experienced problems with their eyes, researchers said. Seven of the nine patients their study focused on had a ...
Wegovy’s label was updated last year to reflect its ability to reduce the risk of cardiovascular events like heart attacks and strokes, while Zepbound’s label now includes treatment for ...
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing ...